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1. Introduction 
The stimulation of amylase release from the rodent 
parotid gland by $-adrenergic agonists is believed to be 
mediated by adenosine 3’,5’-cyclic monophosphate 
(cyclic AMP) since they cause accumulation of cyclic 
AMP and their effects on both amylase release and cyclic 
AMP accumulation are enhanced by methylxanthines 
such as theophylline [ 1~ 31 . Exogenous N6 ,02 ‘-dibutyryl 
cyclic AMP (dbc-AMP) also causes amylase release [l] . 
However, use of the last two criteria as evidence for a 
role involving cyclic AMP in mediating hormone action 
must be done with caution since it has been reported 
that methylxanthines might not always act by increas- 
ing cyclic AMP levels [4] . Further, Hilz and Tarnowski 
have observed that dbc-AMP and cyclic AMP can have 
divergent biological effects [ 51 Cyclic AMP has also 
been implicated in the release of amylase from the 
pancrease (see [6] ). 
Although cyclic AMP might mediate the actions of 
certain secretagogues there are indications that some 
of the secretagogues might act by a cyclic AMP 
independent mechanism. For example, the increased 
elevation of cyclic AMP levels in rat parotid pieces 
caused by epinephrine was inhibited eighty per cent 
by EGTA without a resulting inhibition of amylase 
release [ 71. Also, there is considerable evidence that 
cyclic AMP does not mediate the action of all of the 
secretagogues causing amylase release from the pancreas 
[6,8]. Finally, cholinergic agents have no effect on 
cyclic AMP levels in rabbit parotid slices [9], but do 
increase guanosine 3:5’-cyclic monopliospliate (cyclic 
GMP) levels in slices of rat submaxillary glands [IO] 
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and other tissues [ 1 I] This latter observation raises 
the possibility that cyclic GMP might mediate some 
of the actions of secretagogues which do not appear 
to involve cyclic AMP. 
It has recently been shown that a number of 
catecholamine analogues stimulate DNA synthesis in 
mouse parotid tissue without a detectable increase in 
the tissue level of cyclic AMP [ 121 Since in a separate 
series of compounds all of those compounds stimulat- 
ing DNA synthesis also stimulated amylase release [ 131 
the effect of the present series of analogues on the 
release of amylase and on cyclic GMP levels was 
investigated. 
2. Materials and methods 
Male Fels A or Porton mice, aged 3-4 months and 
weighing 26-30 g were used for all studies. Animals 
were kept on a 12 hr light and dark schedule and fed 
ad libitum until 2 hr before the experiment when food 
was withdrawn. Amylase activity was assayed by the 
method of Bernfeld, as previously described [ 131. 
Cyclic AMP, cyclic GMP and DNA were isolated and 
assayed as described elsewhere [ 141 . The following 
compounds were kindly supplied free of charge: Lz-F- 
104 (II), R-007-XL (IV) and Sor-N-49 (V) by the 
Sterling-Winthrop Research Institute; isoetharine (III) 
by Riker Laboratories; mI 39 (VIII) and p1 39 (IX) 
by Boehringer lngelheim Ltd; propranolol by ICI Ltd.; 
and phentolamine by Ciba Laboratories. 
Isoproterenol (I) was purchased from Winthrop 
Laboratories; p-hydroxyephedrine (VII) and dichloro- 
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Table I. Effect of imvoterenol anal,+ upon omylare and cyclic nucleotide \evels in mouse parotid gland and structures 
of the analogs used. 
Three to 6 animals were wed to meowre amylose levels 2 h after compound odministmtion 
and groups of three onimols to determine cyclic nucleotide concentrations. Cyclic AMP levels 
R, / ’ 
0 
:$H-NH-R5 
ore reported in detail elsewhere (12,14), its level was increased 30-fold by isopmterenol; R2 
R3R4 
(-) values represent no significant difference from the control, (--) > 50% of control and (---) 
< w%of control values. Amylase activity is expressed os mg maltose Iibemted/3min/mg DNA 
and cyclic nucleotide levels 01s pmoles cyclic nucleotide/mg DNA. 
Compound Amount 
(ms) 
Subrtituent Gmupr 
R1 R2 R3 R4 R5 
Parotid Cyclic Cyclic GMP 
Amy lare AMP 
15min 
a 2.5mino 15mina 
I 3 OH OH HOH H CH CC”31 ++++ 
2 
70 f 24 0.53 1.29 
II 4.5 OH OH HOH CH3 cH[CH3] 70f 16 ++ 
2 
III 3 OH OH HOH CH2CH3 CH [CH3] 2 421i105 -- 
IV 1.5 OH OH HOH H CH2CH3 1402f316 - 
V 1.5 OH OH HOH CH3 CH3 46Ok 96 - 
VI 4.5 H OH HOH H CH2CH3 16Oi 24 -- 
VII 
VIII 
IX 
X 
XI 
XII 
XIII 
Pilocarpine, 
H20 
1.5 OH H 
3 H OH 
3 OH H 
3 OH OH 
1 OH H 
2 H H 
2 Cl Cl 
1.5 
HOH 
HOH 
HOH 
0 
H2 
HOH 
HOH 
CH3 
H CH;:i3] 
273* 10 - 
2 13oi 43 - 
H ‘“iCH312 135k 68 -- 1.19 0.52 
H CH CCH312 172k 28 - 1.46 0.62 
H 
c L”“313 
1280 f 170 n.d. 
H cH[cH312 81 f 22 -- 0.86 0.45 
H CH iCH312 319* 5 --- 
344* 14 - 0.42 1.22 
1191 * 135 0.44 0.42 
20% EtOH 
0.1 N HCI 
a Time after compound administration 
1122+149 - 
861*203 - 0.29 0.34 
isoproterenol (XIII) from Aldrich Chemical Co. Ltd. 
and S40032 (VI), S3 5 179 (X) and S42439 (XI) from 
Alfred Bader Chemicals. l-Phenyl-Zisopropyl-amino- 
ethanol (XII) was prepared as previously described 
[ 131. All other drugs and fine chemicals were obtained 
from Sigma Chemical Co. Ltd. 
Compounds were dissolved in Ha0 except for VII 
and XI which were dissolved in 20% ethanol, XIII 
which was dissolved in 0.1 N HC 1 and reserpine which 
was dissolved in acid 20% acetone. All were injected 
intraperitoneally in a volume of 0.2 ml. 
3. Results and discussion 
The effect of isoproterenol and a number of its 
analogues upon amylase release, cyclic AMP and cyclic 
CMP levels in the mouse parotid gland are shown in 
table 1. Release of amylase is, indicated by the loss of 
its activity from the gland. Cyclic AMP levels were 
measured at 15 min after compound administration 
as this is at the peak of cyclic AMP concentration 
after isoproterenol injection [ 121. The analogues without 
a stimulator-y effect at 15 min were also without effect 
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at 2.5 min. Compound XII and pilocarpine have no 
effect over a wide time course [ 141. 
Increasing the size of the amino substituent group 
(Rs) had little effect upon the ability to deplete amylase 
or increase cyclic AMP levels and such analogues 
and therefore omitted from table 1. In contrast, reduc- 
ing the size of this substitutuent, as in IV, immediately 
leads to a complete loss of effect on enzyme release 
and cyclic AMP levels. The addition of a substituent 
(R4) on the u-carbon atom has no effect on amylase 
release if a methyl group (II) and is moderately 
inhibitory if an ethyl group (III), while these substituents 
halve and abolish the stimulation in cyclic AMP levels 
respectively. The removal of on: or both of the aromatic 
ring hydroxyl groups has no effect on the ability to 
induce amylase release (VIII, IX, XII) and such a 
modification actually reactivates compounds with 
smaller Rs substituents (VI, VII). Similarly, replace- 
ment of the catechol hydroxyl groups with chlorine 
atoms only partially inactivates (XIII) with respect to 
amylase release. Removal of the hydroxyl substituent 
on the P-carbon atom is also tolerated (X) but removal 
of this group plus one of the ring hydroxyls leads to 
complete inactivation (XI). None of the compounds VI 
to XIII has any stimulatory effect on cyclic AMP 
levels. Pilocarpine, a compound structurally unrelated 
to isoproterenol, causes a sympathetic system-mediated 
secretion by an indirect action via the superior cervical 
ganglion [ 151. It also has no effect on cyclic AMP levels 
in agreement with Guidotti et al. [ 161 .
Although a redistribution of cyclic AMP resulting 
in a local increase in concentration cannot be ruled 
out, this would seem to be made less likely by the fact 
that compounds VI, IX, XII & XIII actually decrease 
the concentration of cyclic AMP in the parotid and 
analogues with no effect on cyclic AMP in vivo do not 
activate adenylate cyclase in vitro [ 121. 
An alternative mechanism would therefore seem to 
be operating to mediate the stimulation of secretion by 
many, and possibly all, of the compounds tested. An 
increase in the intracellular concentration of cyclic 
GMP could be such a mechanism. Cholinergic agents 
increase the concentration of cyclic GMP in many 
tissues, including the submaxillary gland [lo] . However 
in all systems so far tested isoproterenol has been found 
to have no effect on or actually to inhibit increases in, 
cyclic GMP levels [ 1 l] . By contrast, isoproterenol 
produces a 3-fold increase in the level of cyclic GMP 
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in the parotid. Compounds IX, X, XII as well as pilo- 
carpine also increase the cyclic GMP concentration 
(table 1). To our knowledge this is the first report of a 
possible role for cyclic GMP in amylase release from 
the parotid gland. Butcher (unpublished observations) 
has shown that cu-adrenergic and cholinergic agents 
increase the cyclic GMP level in rat parotid slices. The 
composition of the saliva secreted after /3-adrenergic 
stimulation is quite distinct from that secreted after 
either cholinergic or a-adrenergic stimulation. The 
former is very concentrated with a high ratio of amylase 
to saliva volume while the latter stimulation leads to 
a low ratio of amylase concentration to saliva volume. 
In the submaxillary gland the duct cells are responsible 
for the major part of the water transfer which is 
characteristic of cholinergic and a-adrenergic secretion 
[ 171. The acinar and ductal mechanisms for water 
transfer are under separate control [ 171 . The acinar 
cells of the parotid are innervated through close contacts 
with both adrenergic and cholinergic nerves suggesting 
a dual functional innervation [ 181. In an attempt to 
separate out different stimulator-y mechanisms the 
effects of the a-adrenergic blocking agent, phentola- 
mine, the /3-adrenergic antagonist, propranolol; the 
cholinergic antagonist, atropine; and reserpine which 
depletes the endogenous catecholamine stores on the 
secretion of amylase from the parotid was studied 
(table 2). Depletion of amylase by compounds I and 
IX was unaffected by atropine and phentolamine and 
reserpine had only a small effect but propranolol 
inhibited strongly suggesting that these compounds 
are directly acting /&agonists. Secretion of amylase 
induced by V and X was completely inhibited by both 
reserpine and propranolol, suggesting the possible media- 
tion by endogenous catecholamine release resulting in 
P-adrenergic activation. Secretion caused by XII and 
pilocarpine was largely but not completely inhibited 
by reserpine and propranolol and there was a partial 
inhibition by atropine suggesting a parasympathetic 
component as is known to exist with pilocarpine. 
These results suggest hat differing catecholamine 
analogues may have different modes of action and that 
cyclic GMP may be involved in mediating some of 
their actions while cyclic AMP is not involved. However 
the effects are extremely complex and are no doubt 
further complicated by the fact that calcium ions are 
also known to play a role in controlling secretion 
[7,191. 
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Table 2 
Effect of inhibitors on the depletion of parotid amylase by catecholamine analogues 
Antagonist 
None Phentolamine Reserpine Atropine Propranolol 
Agonist Amount 2 0.1 1 2 
(ma) 
mg maltose liberated/3 min/mg DNA 
H,O _ 1095 560 1194 1433 1015 
1 1 73 24 332 64 806 
V 1 483 206 955 751 1203 
1X 1 117 29 298 201 912 
X 1 274 49 1281 504 1261 
XII 2 157 243 761 615 937 
pilocarpine 1 535 69 962 921 864 
Inhibitors were administered 10 min prior to the analogues, except for reserpine which was given 
24 hr previously. Other conditions were as described under Materials and methods and in table 1. 
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